Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

• Results Overview

  Both doses of oral abrocitinib (100mg and 200mg daily) were more effective than placebo in treating moderate-to-severe eczema, with the 200mg dose showing faster itch relief than dupilumab, though both treatments had similar overall effectiveness at 16 weeks.

• Study Summary

  Num Participants:

  838

  Study Type:

  Rct

  Control Group:

  ['Placebo', 'Dupilumab 300mg Subcutaneous Every Other Week', 'Abrocitinib 100mg Oral Daily']

  Efficacy End Points Treatment:

  {'IGA response': 48.4, 'EASI-75': 70.3}

  Efficacy End Points Control:

  {'IGA response': 14.0, 'EASI-75': 27.1}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nausea	Low	11.1
  Acne	Low	6.6

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Nausea	Low	4.2
  Acne	Low	2.9